Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
Provides osmotic gradient for peritoneal dialysis via hyperosmolar dextrose solution; dextrose is absorbed and metabolized, driving ultrafiltration of excess fluid and solutes across peritoneal membrane.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 liters of 2.5% dextrose solution per exchange, 4 exchanges daily (8 liters total per day) for continuous ambulatory peritoneal dialysis (CAPD).
None Documented
None Documented
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Not applicable as a continuous dialysis solution; systemic glucose half-life ~1.5-2 hours in normal physiology, but prolonged in renal impairment.
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Renal (predominantly via dialysate effluent); peritoneal dialysis removes glucose and metabolites. Less than 5% metabolized; no significant biliary or fecal excretion.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution